The Chronic Lymphocytic Leukemia (CLL) Genome Project aims to generate a comprehensive catalogue of genomic alterations involved in the development and progression of the disease. This information will improve our ability to diagnose and categorize the patients and will promote the advance in new therapeutic approaches.
The CLL Genome Project, as a contributing member of the International Cancer Genome Consortium (ICGC), has the purposes of creating diagnostic tools, discovering therapeutic targets and developing new strategies that will allow a customized therapy for CLL in order to make it more precise and effective.
17 March 2013
For the first time, the CLL Consortium associates cancer with failure in the protection of chromosomes
The study published today in Nature Genetics explores a new mechanism that may contribute to the development of diverse tumors. The researchers report recurrent mutations in POT1 in chronic lymphocytic leukemia. This is the first member of the telomeric shelterin complex reported to be mutated in human cancer. Link to the study.
|CLL Genome Project is funded by the Spanish Ministry of Economy and Competitivity through the Institute of Health Carlos III (ISCiii).|